

## ANNEX 1 to PROTOCOL B2311061 (EU Drug Utilization Study)

**Table 3. Study Variables available by Country and Data Source**

<b>Patient characteristics</b>	<b>Belgium</b>	<b>Finland</b>	<b>France</b>	<b>Germany</b>	<b>Italy<sup>a</sup></b>	<b>Netherlands</b>	<b>Spain<sup>a</sup></b>	<b>Sweden</b>	<b>UK</b>
Age	MPI <sup>h</sup>	LRx	LRx	DA, LRx	LRx MPI	Xponent MPI	LRx MPI	NDR	THIN
Gender	MPI	LRx	DA	DA, LRx	LRx MPI	Xponent MPI	LRx MPI	NDR	THIN
Indication	MPI <sup>c</sup>	LRx	DA	DA	MPI <sup>c</sup>	MPI <sup>c</sup>	MPI <sup>c</sup>	NDR/ NPR <sup>b,c</sup>	THIN
Height/ weight/ body mass index			DA <sup>e</sup>	DA <sup>e</sup>					THIN <sup>e</sup>
Comorbidities (osteoporosis, CVD, hyperlipidemia, hypertension, breast pain, diabetes, renal disease, osteoarthritis, major depression)		LRx <sup>e</sup>	DA	DA			LRx <sup>d</sup>	hospital in and outpatient setting: NPR; primary care: NDR (through co medication <sup>b</sup> )	THIN

**Table 3. Study Variables available by Country and Data Source**

	Belgium	Finland	France	Germany	Italy <sup>a</sup>	Netherlands	Spain <sup>a</sup>	Sweden	UK
<b>Patient characteristics</b>									
<b>Concomitant medication</b> (corticosteroids, lipid lowering agents, antihypertensives, antidepressants, sedatives/hypnotics, antidiabetics, local hormone treatments, osteoporosis treatments)	LRx	LRx	LRx	DA LRx	LRx	Xponent (copre- scriptions)	LRx	NDR (for retail, not hospital products)	THIN
History of VTE/CVA/CHD event	LRx <sup>d</sup>	LRx <sup>e</sup>	DA	DA				NPR	THIN
History of malignancy potentially associated with oestrogen		LRx <sup>e</sup>	DA <sup>e</sup>	DA <sup>e</sup>				NPR	THIN <sup>e</sup>
Past use of E+P HRT	LRx	LRx	DA <sup>e</sup> LRx	DA LRx	LRx	Xponent	LRx	NDR	THIN
Switchers from E+P HRT	LRx	LRx	LRx	DA LRx	LRx	Xponent	LRx	NDR	THIN
<b>Drug utilization</b>									
Duavive or oestrogen/progestin prescription date	LRx <sup>f</sup>	LRx <sup>g</sup>	LRx <sup>f</sup>	DA LRx <sup>f</sup>	LRx <sup>f</sup>	Xponent <sup>f</sup>	tbd	NDR	THIN

**Table 3. Study Variables available by Country and Data Source**

Patient characteristics	Belgium	Finland	France	Germany	Italy <sup>a</sup>	Netherlands	Spain <sup>a</sup>	Sweden	UK
Duavive or oestrogen/progestin prescribed dose	LRx	LRx	DA LRx <sup>d</sup>	DA LRx		Xponent	LRx <sup>d</sup>	NDR <sup>d</sup>	THIN
Duavive or oestrogen/progestin prescribed days supply	LRx <sup>d</sup>		LRx	DA LRx		Xponent	tbd	NDR <sup>d</sup>	THIN <sup>d</sup>

- a. Only reimbursed prescriptions in LRx Spain and LRx Italy.
- b. Linking required
- c. If direct link between drug and diagnosis is missing, inference is made based on co-occurring diagnosis
- d. Can only be inferred
- e. Some missing information expected
- f. Dispense date.
- g. Only month of prescription
- h. Only standard age groups

CHD=Coronary Heart Disease; CVA=Cerebrovascular Accident; CVD= Cardiovascular Disease; DA=IMS Disease Analyzer (Data Source); E+P HRT=Oestrogen/Progestin Hormone Replacement Therapy; IMS=Intercontinental Marketing Services; LRx=IMS Longitudinal Prescription Data; MPI= Midas Prescribing Insights (Data Source); NDR=National Drug Register (Sweden); NPR= National Patient Register (Sweden); tbd=to be determined; THIN=The Health Improvement Network; VTE=Venous Thromboembolism.

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

Belgium	Data bases used: LRx and MIDAS PI/ Medical Index	Diagnostic Codes (if applicable)
<b>Rationale for choice of data base:</b>	LRx will provide longitudinal prescription information but not diagnoses, therefore use of MIDAS PI/Medical Index in addition is recommended in order to obtain this information. MIDAS PI/ Medical Index is a cross-sectional, retrospective medical information database providing regular snapshots of doctor-patient consultations.	
<b>Objective/analysis:</b>		
<i>Patient age</i>	For data protection reasons, only standard age groups for a given medication are provided	
<i>Cardiovascular risk factors (Height/ weight/ body mass index)</i>	No suitable data source for height/ weight/ body mass index available in country	
<i>History of CVD event</i>	Not directly, but inference through medication in LRx in the patient’s history may give some information	
<i>History of malignancy potentially associated with oestrogen</i>	Only available if diagnosed in the same consultation (MPI)	ICD-10 Codes: C50, C54, C54.1, C56, C57.8, C57.9
<i>Indication for use</i>	MPI; if direct link between drug and diagnosis is missing, inference is made based on co-occurring diagnosis	
<i>Comorbidities</i>	Available in MPI, if diagnosed in the same consultation; not directly in LRx, but inference through comedication may give some information	
<i>Other current or recent drug therapies</i>	LRx	
<i>Use of E+P HRT</i>	LRx	
<b>Off-label use</b>	<b>Variable used to address off-label use (database):</b>	
<i>Use for treatment of osteoporosis.</i>	Indication (MPI), if diagnosed in same consultation	ICD-10 Codes: M80-M82

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<i>Use in pre-menopausal women</i>	Inference by age in other countries, but age is not available in Belgium due to data protection reasons	
<i>Use in women without a uterus (hysterectomised women)</i>	Not available	
<i>Use in males</i>	MPI	
<i>Use in women over 75 years old.</i>	Not available	
<i>Use of non-approved dose (i.e. more than one pill per day, divided tablets)</i>	Dose (LRx)	
<i>Use with progestins, additional oestrogens or selective oestrogen receptor modulators (SERMs)</i>	Concomitant medication (LRx)	
<i>Use in women with any of the following contraindicated conditions:</i>		
<i>Known, suspected, or past history of breast cancer.</i>	Only available, if diagnosed in the same consultation (MPI)	ICD-10 Codes: C50, Z85.3
<i>Use for prevention of breast cancer.</i>	not available	
<i>Hypersensitivity (e.g. anaphylaxis/anaphylactoid reactions, urticaria, drug eruption) to the active substances or to any of the excipients.</i>	Only available if diagnosed in the same consultation (MPI)	ICD-10 Codes: T78.2, T88.6, L50.0, L50.1, L50.9
<i>History of malignancy potentially associated with oestrogen</i>	Only available if diagnosed in the same consultation (MPI)	ICD-10 Codes: C50, C54, C54.1, C56, C57.8, C57.9
<i>Active or past history of venous thromboembolism (deep venous thrombosis, pulmonary embolism, and retinal vein thrombosis); active or past history of arterial thromboembolic disease (e.g., myocardial infarction, stroke); acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal.</i>	Only available, if diagnosed in the same consultation (MPI); not directly in LRx, but inference through comedication may give some information	ICD-10 codes: I80 (I80.0), I81, I82, I26, H34.8, H34.9, I21, I22, I61, I62, I63, I64, K71, K72, K75.0, K76.2, K76.3
<i>Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency).</i>	Not available	

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<i>Women of childbearing potential.</i>	Inference by age in other countries, but age is not available in Belgium due to data protection reasons	
<i>Porphyria.</i>	Available, if diagnosed in the same consultation (MPI)	ICD-10 codes: E80.0, E80.1, E80.2
<b>Finland</b>	<b>Data base: LRx Finland</b>	<b>Diagnostic Codes (if applicable)</b>
<b>Rationale for choice of data base:</b>	LRx will provide prescription information including indication	
<b>Objective/analysis:</b>		
<i>Patient age</i>	LRx	
<i>Cardiovascular risk factors (Height/ weight/ body mass index)</i>	No suitable data source for height/ weight/ body mass index available in country	
<i>History of CVD event</i>	LRx	ICD-10 Codes: I61-I64, I21.x, I22.0, I22.1, I22.8, I22.9
<i>History of malignancy potentially associated with oestrogen</i>	LRx	ICD-10 Codes: C50, C54, C54.1, C56, C57.8, C57.9
<i>Indication for use</i>	Determined by presence of diagnostic codes for estrogen deficiency or osteoporosis 90 days before or after drug initiation. Four levels for this variable: -Oestrogen deficiency symptoms only -Osteoporosis only -Both -Unknown	ICD-10 codes: <ul style="list-style-type: none"> <li>• Osteoporosis: M80-M82</li> <li>• Oestrogen Deficiency Symptoms: N95.1, N95.9, R23.3</li> </ul>
<i>Comorbidities</i>	LRx	
<i>Other current or recent drug therapies</i>	LRx	
<i>Use of E+P HRT</i>	LRx	
<b>Off-label use</b>	<b>Variable used to address off-label use:</b>	

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<i>Use for treatment of osteoporosis.</i>	Indication (LRx)	ICD-10: M80-M82
<i>Use in pre-menopausal women</i>	Inference by age (LRx)	
<i>Use in women without a uterus (hysterectomised women)</i>	Not available	
<i>Use in males</i>	Gender (LRx)	
<i>Use in women over 75 years old.</i>	Age (LRx)	
<i>Use of non-approved dose (i.e. more than one pill per day, divided tablets)</i>	Dose (LRx)	
<i>Use with progestins, additional oestrogens or selective oestrogen receptor modulators (SERMs)</i>	Concomitant medication (LRx)	
<i>Use in women with any of the following contraindicated conditions:</i>		
<i>Known, suspected, or past history of breast cancer.</i>	LRx	ICD-10 Codes: C50, Z85.3
<i>Use for prevention of breast cancer.</i>	not available	
<i>Hypersensitivity (e.g. anaphylaxis/anaphylactoid reactions, urticaria, drug eruption) to the active substances or to any of the excipients.</i>	Not available	ICD-10 Codes: T78.2, T88.6, L50.0, L50.1, L50.9
<i>History of malignancy potentially associated with oestrogen</i>	LRx	ICD-10 Codes: C50, C54, C54.1, C56, C57.8, C57.9
<i>Active or past history of venous thromboembolism (deep venous thrombosis, pulmonary embolism, and retinal vein thrombosis); active or past history of arterial thromboembolic disease (e.g., myocardial infarction, stroke); acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal.</i>	LRx	ICD-10 codes: I80 (I80.0), I81, I82, I26, H34.8, H34.9, I21, I22, I61, I62, I63, I64, K71, K72, K75.0, K76.2, K76.3
<i>Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency).</i>	Not available	
<i>Women of childbearing potential.</i>	Inference by age (LRx)	
<i>Porphyria.</i>	LRx	ICD-10 codes: E80.0, E80.1, E80.2

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<b>France</b>	<b>Data bases: DA and LRx</b>	<b>Diagnostic Codes (if applicable)</b>
<b>Rationale for choice of data bases:</b>	DA comprises patient level longitudinal data which can answer all the drug utilisation study questions raised. In France, it includes GPs only, therefore IMS recommends to also include LRx, which also covers specialists.	
<b>Objective/analysis:</b>		
<i>Patient age</i>	LRx	
<i>Cardiovascular risk factors</i> (Height/ weight/ body mass index)	Possible in DA, but missing information is expected	
<i>History of CVD event</i>	DA	ICD-10 Codes: I61-I64, I21.x, I22.0, I22.1, I22.8, I22.9
<i>History of malignancy potentially associated with oestrogen</i>	DA	ICD-10 Codes: C50, C54, C54.1, C56, C57.8, C57.9
<i>Indication for use</i>	Determined by presence of diagnostic codes for estrogen deficiency or osteoporosis 90 days before or after drug initiation. Four levels for this variable: -Oestrogen deficiency symptoms only -Osteoporosis only -Both -Unknown	ICD-10 codes: <ul style="list-style-type: none"> <li>• Osteoporosis: M80-M82</li> <li>• Oestrogen Deficiency Symptoms: N95.1, N95.9, R23.3</li> </ul>
<i>Comorbidities</i>	DA	
<i>Other current or recent drug therapies</i>	LRx	
<i>Use of E+P HRT</i>	DA LRx	
<b>Off-label use</b>	<b>Variable used to address off-label use (database):</b>	
<i>Use for treatment of osteoporosis</i>	Indication (DA)	ICD-10: M80-M82
<i>Use in pre-menopausal women</i>	Inference by age (LRx)	



**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<i>Use in women without a uterus (hysterectomised women)</i>	Comorbidities ( DA)	
<i>Use in males</i>	Gender (DA)	
<i>Use in women over 75 years old.</i>	Age (LRx)	
<i>Use of non-approved dose (i.e. more than one pill per day, divided tablets)</i>	Dose can be inferred (DA, LRx)	
<i>Use with progestins, additional oestrogens or selective oestrogen receptor modulators (SERMs)</i>	Concomitant medication (DA, LRx)	
<i>Use in women with any of the following contraindicated conditions:</i>		
<i>Known, suspected, or past history of breast cancer.</i>	Breast cancer (DA)	ICD-10 Codes: C50, Z85.3
<i>Use for prevention of breast cancer.</i>	not available	
<i>Hypersensitivity (e.g. anaphylaxis/anaphylactoid reactions, urticaria, drug eruption) to the active substances or to any of the excipients.</i>	Comorbidities (DA)	ICD-10 Codes: T78.2, T88.6, L50.0, L50.1, L50.9
<i>History of malignancy potentially associated with oestrogen</i>	Comorbidities (DA)	ICD-10 Codes: C50, C54, C54.1, C56, C57.8, C57.9
<i>Active or past history of venous thromboembolism (deep venous thrombosis, pulmonary embolism, and retinal vein thrombosis); active or past history of arterial thromboembolic disease (e.g., myocardial infarction, stroke); acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal.</i>	Documentation of these conditions in DA	ICD-10 codes: I80 (I80.0), I81, I82, I26, H34.8, H34.9, I21, I22, I61, I62, I63, I64, K71, K72, K75.0, K76.2, K76.3
<i>Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency).</i>	Documentation of these conditions in DA	ICD-10 codes: D68.5, D68.6
<i>Women of childbearing potential.</i>	Limited inference by age (LRx)	
<i>Porphyria.</i>	Documentation of these conditions in DA	ICD-10 codes: E80.0, E80.1, E80.2

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

Germany	Data bases: DA Germany and LRx	Diagnostic Codes (if applicable)
<b>Rationale for choice of data base:</b>	DA comprises patient level longitudinal data which can answer all the drug utilisation study questions raised, including indication. The sample is representative for Germany and includes GP/Internists and specialists; LRx is used in addition as it provides prescription data across all specialties with an excellent coverage (60% of pharmacies in Germany).	
<b>Objective/analysis:</b>		
<i>Patient age</i>	DA, LRx	
<i>Cardiovascular risk factors</i> (Height/ weight/ body mass index)	Possible in DA, but missing information is expected	
<i>History of CVD event</i>	DA	ICD-10 Codes: I61-I64, I21.x, I22.0, I22.1, I22.8, I22.9
<i>History of malignancy potentially associated with oestrogen</i>	DA	ICD-10 Codes: C50, C54, C54.1, C56, C57.8, C57.9
<i>Indication for use</i>	Determined by presence of diagnostic codes for estrogen deficiency or osteoporosis 90 days before or after drug initiation. Four levels for this variable: -Oestrogen deficiency symptoms only -Osteoporosis only -Both -Unknown	ICD-10 codes: <ul style="list-style-type: none"><li>• Osteoporosis: M80-M82</li><li>• Oestrogen Deficiency Symptoms: N95.1, N95.9, R23.3</li></ul>
<i>Comorbidities</i>	DA	
<i>Other current or recent drug therapies</i>	DA LRx	
<i>Use of E+P HRT</i>	DA LRx	
<b>Off-label use</b>	<b>Variable used to address off-label use (database):</b>	

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<i>Use for treatment of osteoporosis</i>	Indication: ICD-10 code M80-82; (DA)	ICD-10: M80-M82
<i>Use in pre-menopausal women</i>	Inference by age (DA, LRx)	
<i>Use in women without a uterus (hysterectomised women)</i>	ICD-10 code Z90.7 ( DA)	
<i>Use in males</i>	Gender (DA, LRx)	
<i>Use in women over 75 years old.</i>	Age (DA, LRx)	
<i>Use of non-approved dose (i.e. more than one pill per day, divided tablets)</i>	Dose (DA, LRx)	
<i>Use with progestins, additional oestrogens or selective oestrogen receptor modulators (SERMs)</i>	Concomitant medication (DA, LRx)	
<i>Use in women with any of the following contraindicated conditions:</i>		
<i>Known, suspected, or past history of breast cancer.</i>	DA	ICD-10 Codes: C50, Z85.3
<i>Use for prevention of breast cancer.</i>	not available	
<i>Hypersensitivity (e.g. anaphylaxis/anaphylactoid reactions, urticaria, drug eruption) to the active substances or to any of the excipients.</i>	DA	ICD-10 Codes: T78.2, T88.6, L50.0, L50.1, L50.9
<i>History of malignancy potentially associated with oestrogen</i>	DA	ICD-10 Codes: C50, C54, C54.1, C56, C57.8, C57.9
<i>Active or past history of venous thromboembolism (deep venous thrombosis, pulmonary embolism, and retinal vein thrombosis); active or past history of arterial thromboembolic disease (e.g., myocardial infarction, stroke); acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal.</i>	DA	ICD-10 codes: I80 (I80.0), I81, I82, I26, H34.8, H34.9, I21, I22, I61, I62, I63, I64, K71, K72, K75.0, K76.2, K76.3
<i>Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency).</i>	DA	ICD-10 codes: D68.5, D68.6
<i>Women of childbearing potential.</i>	Limited inference by age (DA, LRx)	
<i>Porphyria.</i>	Documentation of these conditions in DA	ICD-10 codes: E80.0, E80.1, E80.2

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

Italy	Data bases: LRx and MIDAS PI	Diagnostic Codes (if applicable)
<b>Rationale for choice of data bases:</b>	LRx will provide prescription information of reimbursed drugs, but no indication. Therefore use of MIDAS PI/Medical Index in addition is recommended in order to obtain this information.	
<b>Objective/analysis:</b>		
<i>Patient age</i>	LRx MPI	
<i>Cardiovascular risk factors (Height/ weight/ body mass index)</i>	No suitable data source for height/ weight/ body mass index available in country	
<i>History of CVD event</i>	Not directly, but inference through medication in LRx in the patient's history may give some information	
<i>History of malignancy potentially associated with oestrogen</i>	Only available, if diagnosed in the same consultation (MPI); not available in LRx	ICD-10 Codes: C50, C54, C54.1, C56, C57.8, C57.9
<i>Indication for use</i>	MPI; up to 3 digit ICD-10 code; if direct link between drug and diagnosis is missing, inference is made based on co-occurring diagnosis;	
<i>Comorbidities</i>	In MPI, if diagnosed in the same consultation; not directly in LRx, but inference through comedication may give some information	
<i>Other current or recent drug therapies</i>	LRx	
<i>Use of E+P HRT</i>	LRx	
<b>Off-label use</b>	<b>Variable used to address off-label use (database):</b>	
<i>Use for treatment of osteoporosis</i>	Indication (MPI), if diagnosed in same consultation	ICD-10 Codes: M80-M82
<i>Use in pre-menopausal women</i>	Inference by age (MPI, LRx)	
<i>Use in women without a uterus (hysterectomised women)</i>	Not available	
<i>Use in males</i>	MPI, LRx	
<i>Use in women over 75 years old.</i>	MPI, LRx	

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<i>Use of non-approved dose (i.e. more than one pill per day, divided tablets)</i>	Not available	
<i>Use with progestins, additional oestrogens or selective oestrogen receptor modulators (SERMs)</i>	Concomitant medication (LRx)	
<i>Use in women with any of the following contraindicated conditions:</i>		
<i>Known, suspected, or past history of breast cancer.</i>	Only available, if diagnosed in the same consultation (MPI); not available in LRx	ICD-10 Codes: C50, Z85.3
<i>Use for prevention of breast cancer.</i>	Not available	
<i>Hypersensitivity (e.g. anaphylaxis/anaphylactoid reactions, urticaria, drug eruption) to the active substances or to any of the excipients.</i>	Not available	
<i>History of malignancy potentially associated with oestrogen</i>	Only available, if diagnosed in the same consultation (MPI); not available in LRx	ICD-10 Codes: C50, C54, C54.1, C56, C57.8, C57.9
<i>Active or past history of venous thromboembolism (deep venous thrombosis, pulmonary embolism, and retinal vein thrombosis); active or past history of arterial thromboembolic disease (e.g., myocardial infarction, stroke); acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal.</i>	Only available, if diagnosed in the same consultation (MPI); not directly in LRx, but inference through comedication may give some information	ICD-10 codes: I80 (I80.0), I81, I82, I26, H34.8, H34.9, I21, I22, I61, I62, I63, I64, K71, K72, K75.0, K76.2, K76.3
<i>Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency).</i>	Not available	
<i>Women of childbearing potential.</i>	Limited inference by age (MPI, LRx)	
<i>Porphyria.</i>	Not available	

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

Netherlands	Data bases used: Xponent™ and MIDAS PI/ Medical Index	Diagnostic Codes (if applicable)
Rationale for choice of data base:	Xponent includes prescription data of over 75% of retail pharmacies and dispensing GPs (more than 14.5 million prescriptions per month). Prescriptions by both specialists and GPs are covered. For information about indication, it is recommended to use MIDAS PI/ Medical Index in addition.	
Objective/analysis:		
Patient age	Xponent MPI	
Cardiovascular risk factors (Height/ weight/ body mass index)	No suitable data source for height/ weight/ body mass index available in country	
History of CVD event	Not directly, but inference through medication in Xponent in the patient’s history may give some information	
History of malignancy potentially associated with oestrogen	Only available, if diagnosed in the same consultation (MPI); not available in Xponent	ICD-10 Codes: C50, C54, C54.1, C56, C57.8, C57.9
Indication for use	MPI; if direct link between drug and diagnosis is missing, inference is made based on co-occurring diagnosis	
Comorbidities	In MPI, if diagnosed in the same consultation; not directly in Xponent, but inference through comedication may give some information	
Other current or recent drug therapies	Xponent (co-prescriptions)	
Use of E+P HRT	Xponent (3 years of backdata)	
Off-label use	Variable used to address off-label use (database):	

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<i>Use for treatment of osteoporosis</i>	Indication (MPI), if diagnosed in same consultation	ICD-10 Codes: M80-M82
<i>Use in pre-menopausal women</i>	Inference by age (MPI)	
<i>Use in women without a uterus (hysterectomised women)</i>	Not available	
<i>Use in males</i>	MPI	
<i>Use in women over 75 years old.</i>	MPI	
<i>Use of non-approved dose (i.e. more than one pill per day, divided tablets)</i>	Dose (LRx)	
<i>Use with progestins, additional oestrogens or selective oestrogen receptor modulators (SERMs)</i>	Concomitant medication (LRx)	
<i>Use in women with any of the following contraindicated conditions:</i>		
<i>Known, suspected, or past history of breast cancer.</i>	Only available, if diagnosed in the same consultation (MPI); not available in Xponent	ICD-10 Codes: C50, Z85.3
<i>Use for prevention of breast cancer.</i>	Not available	
<i>Hypersensitivity (e.g. anaphylaxis/anaphylactoid reactions, urticaria, drug eruption) to the active substances or to any of the excipients.</i>	Not available	
<i>History of malignancy potentially associated with oestrogen</i>	Only available, if diagnosed in the same consultation (MPI); not available in Xponent	ICD-10 Codes: C50, C54, C54.1, C56, C57.8, C57.9
<i>Active or past history of venous thromboembolism (deep venous thrombosis, pulmonary embolism, and retinal vein thrombosis); active or past history of arterial thromboembolic disease (e.g., myocardial infarction, stroke); acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal.</i>	Only available, if diagnosed in the same consultation (MPI); not directly in Xponent, but inference through comedication may give some information	ICD-10 codes: I80 (I80.0), I81, I82, I26, H34.8, H34.9, I21, I22, I61, I62, I63, I64, K71, K72, K75.0, K76.2, K76.3
<i>Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency).</i>	Not available	

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<i>Women of childbearing potential.</i>	Limited inference by age (MPI, LRx)	
<i>Porphyria.</i>	Not available	
<b>Spain</b>	<b>Data base used: LRx and MIDAS PI</b>	<b>Diagnostic Codes (if applicable)</b>
<b>Rationale for choice of data base:</b>	IMS recommends using LRx data to get prescription information. As this information does not include indication, it is recommended to use MIDAS PI in addition. Nevertheless, the overall coverage of LRx in Spain is relatively low (7% of prescriptions), therefore a final decision can only be made after a feasibility assessment has been performed.	
<b>Objective/analysis:</b>		
<i>Patient age</i>	LRx MPI	
<i>Cardiovascular risk factors (Height/ weight/ body mass index)</i>	No suitable data source for height/ weight/ body mass index available in country	
<i>History of CVD event</i>	Not directly, but inference through medication in LRx in the patient's history may give some information	
<i>History of malignancy potentially associated with oestrogen</i>	Only available, if diagnosed in the same consultation (MPI); not available in LRx	ICD-10 Codes: C50, C54, C54.1, C56, C57.8, C57.9
<i>Indication for use</i>	MPI; If direct link between drug and diagnosis is missing, inference is made based on co-occurring diagnosis	
<i>Comorbidities</i>	In MPI, if diagnosed in the same consultation; not directly in LRx, but inference through comedication may give some information	
<i>Other current or recent drug therapies</i>	LRx	
<i>Use of E+P HRT</i>	LRx	
<b>Off-label use</b>	<b>Variable used to address off-label use (database):</b>	
<i>Use for treatment of osteoporosis</i>	MPI (indication), if diagnosed in same consultation	ICD-10 Codes: M80-M82



**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<i>Use in pre-menopausal women</i>	Inference by age (MPI)	
<i>Use in women without a uterus (hysterectomised women)</i>	Not available	
<i>Use in males</i>	MPI	
<i>Use in women over 75 years old.</i>	MPI	
<i>Use of non-approved dose (i.e. more than one pill per day, divided tablets)</i>	Dose (LRx)	
<i>Use with progestins, additional oestrogens or selective oestrogen receptor modulators (SERMs)</i>	Concomitant medication (LRx)	
<i>Use in women with any of the following contraindicated conditions:</i>		
<i>Known, suspected, or past history of breast cancer.</i>	Only available, if diagnosed in the same consultation (MPI); not available in LRx	ICD-10 Codes: C50, Z85.3
<i>Use for prevention of breast cancer.</i>	not available	
<i>Hypersensitivity (e.g. anaphylaxis/anaphylactoid reactions, urticaria, drug eruption) to the active substances or to any of the excipients.</i>	Not available	
<i>History of malignancy potentially associated with oestrogen</i>	Only available, if diagnosed in the same consultation (MPI); not available in LRx	ICD-10 Codes: C50, C54, C54.1, C56, C57.8, C57.9
<i>Active or past history of venous thromboembolism (deep venous thrombosis, pulmonary embolism, and retinal vein thrombosis); active or past history of arterial thromboembolic disease (e.g., myocardial infarction, stroke); acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal.</i>	Only available, if diagnosed in the same consultation (MPI); not directly in LRx, but inference through comedication may give some information	ICD-10 codes: I80 (I80.0), I81, I82, I26, H34.8, H34.9, I21, I22, I61, I62, I63, I64, K71, K72, K75.0, K76.2, K76.3
<i>Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency).</i>	Not available	
<i>Women of childbearing potential.</i>	Limited inference by age (MPI, LRx)	
<i>Porphyria.</i>	Not available	

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

Sweden	Data bases: National Drug Register and National Patient Register	Diagnostic Codes (if applicable)
<b>Rationale for choice of data base:</b>	The National Patient Register has national coverage of all care provided at hospitals in Sweden, including both out- and inpatient setting. The National Drug Register includes all dispensed prescriptions from Swedish pharmacies, including prescriptions issued in both primary care and from secondary care (including hospitals). Linking of data from the National Drug Register and the National Patient Register will allow inferring of indication for patients who received their Duavive prescription from a hospital covered by the National Patient Register.	
<i>Objective/analysis:</i>		
<i>Patient age</i>	NDR	
<i>Cardiovascular risk factors (Height/ weight/ body mass index)</i>	No suitable data source for height/ weight/ body mass index available in country	
<i>History of CVD event</i>	Available for patients in NPR	ICD-10 Codes: I61-I64, I21.x, I22.0, I22.1, I22.8, I22.9
<i>History of malignancy potentially associated with oestrogen</i>	Available for patients in NPR	ICD-10 Codes: C50, C54, C54.1, C56, C57.8, C57.9
<i>Indication for use</i>	Determined by presence of diagnostic codes for estrogen deficiency or osteoporosis 90 days before or after drug initiation. Four levels for this variable: -Oestrogen deficiency symptoms only -Osteoporosis only -Both -Unknown	ICD-10 codes: <ul style="list-style-type: none"> <li>• Osteoporosis: M80-M82</li> <li>• Oestrogen Deficiency Symptoms: N95.1, N95.9, R23.3</li> </ul>
<i>Comorbidities</i>	hospital in- and outpatient setting: NPR; primary care: NDR (through inference by comedication)	

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<i>Other current or recent drug therapies</i>	NDR (for retail, not hospital products)	
<i>Use of E+P HRT</i>	NDR	
<b>Off-label use</b>	<b>Variable used to address off-label use (database):</b>	
<i>Use for treatment of osteoporosis</i>	Available for patients in NPR; linking of data bases required (NPR/ NDR)	ICD-10: M80-M82
<i>Use in pre-menopausal women</i>	Inference by age (NDR)	
<i>Use in women without a uterus (hysterectomised women)</i>	Not available	
<i>Use in males</i>	NDR	
<i>Use in women over 75 years old.</i>	NDR	
<i>Use of non-approved dose (i.e. more than one pill per day, divided tablets)</i>	Inference (NDR)	
<i>Use with progestins, additional oestrogens or selective oestrogen receptor modulators (SERMs)</i>	Concomitant medication (NDR)	
<i>Use in women with any of the following contraindicated conditions:</i>		
<i>Known, suspected, or past history of breast cancer.</i>	NPR	ICD-10 Codes: C50, Z85.3
<i>Use for prevention of breast cancer.</i>	Not available	
<i>Hypersensitivity (e.g. anaphylaxis/anaphylactoid reactions, urticaria, drug eruption) to the active substances or to any of the excipients.</i>	Linking of data bases required (NPR/ NDR), incomplete information expected	ICD-10 Codes: T78.2, T88.6, L50.0, L50.1, L50.9
<i>History of malignancy potentially associated with oestrogen</i>	NPR	ICD-10 Codes: C50, C54, C54.1, C56, C57.8, C57.9
<i>Active or past history of venous thromboembolism (deep venous thrombosis, pulmonary embolism, and retinal vein thrombosis); active or past history of arterial thromboembolic disease (e.g., myocardial infarction, stroke); acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal.</i>	Available for patients in NPR; linking of data bases required (NPR/ NDR)	ICD-10 codes: I80 (I80.0), I81, I82, I26, H34.8, H34.9, I21, I22, I61, I62, I63, I64, K71, K72, K75.0, K76.2, K76.3

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<i>Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency).</i>	Linking of data bases required (NPR/ NDR), incomplete information expected	ICD-10 codes: D68.5, D68.6
<i>Women of childbearing potential.</i>	Limited inference by age (NDR)	
<i>Porphyria.</i>	Linking of data bases required (NPR/ NDR), incomplete information expected	ICD-10 codes: E80.0, E80.1, E80.2
<b>United Kingdom</b>	<b>Data base: UK THIN</b>	<b>READ Codes (if applicable)</b>
<b>Rationale for choice of data base:</b>	The Health Improvement Network (THIN) data is comprised of pseudonymised patient data collected in a non-interventional manner from the daily record keeping of general practices in the UK. Overall, THIN contains data on almost 6% of the UK population. A number of practices providing data for THIN have been linked to HES (hospital episode statistics) data. Data attributes available to researchers consist of demographic, medical and prescription information at the individual patient-level. In addition, there is information on referral to specialists, hospitalisation, diagnostics and laboratory results, some lifestyle characteristics and other measurements taken in the GP practice. Clinical information is recorded via the Read disease classification system and issued prescriptions via the GEMscript drug code system.	
<b>Objective/analysis:</b>		
<i>Patient age</i>	Available	
<i>Cardiovascular risk factors (Height/ weight/ body mass index)</i>	Some availability, some missing information expected	

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<i>History of CVD event</i>	Comorbidities	<p>READ:</p> <p>G63y0,G63y1,G6W.,Gyu6G.,G6W.,G6400,G6410,G6X.,Gyu63,G6760,Gyu64,G64z4,G64z.,G64z0,G64z2,G64z3,G664.,G610.,G61X.,G61X0,G61X1,Gyu6F,G614.,G615.,G613.,G617.,G618.,Gyu62,G619.,G61.,G61z.,G621.,G622.,G623.,G620.,G62.,G62z,G611.,G612.,G616.,G350.,G351.,G353.,Gyu35,G35.,G35X.,Gyu36,0.3233,G300.,G301.,G3010,G3011,G301z,G380.,G302.,G303.,G308.,G30yz,G381.,0.3234,0.3236,G304.,G305.,G306.,G30y2,G382.,G30B.,G309.,G30X.,G30X0,G383.,Gyu34,0.3235,G307.,G3070,G3071,G30y1,G384.,G30.,G30A.,G30y.,G30y0,G30z.,G38.,G38z.</p>
<i>History of malignancy potentially associated with oestrogen</i>	Comorbidities	<p>READ:</p> <p>B430200; B832000; B430211; K5A1.; K5A6.; N3323; N33zA; N333.; N3330; N3331</p> <p>N333z</p>

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<i>Indication for use</i>	<p>Determined by presence of diagnostic codes for estrogen deficiency or osteoporosis 90 days before or after drug initiation.</p> <p>Four levels for this variable:</p> <ul style="list-style-type: none"> <li>-Oestrogen deficiency symptoms only</li> <li>-Osteoporosis only</li> <li>-Both</li> <li>-Unknown</li> </ul>	<p>READ:</p> <p>K5A1.,K5A6.,1512.,66U3.,66U7.,66U9.,66UB.,66UC.,8B64.,J773,8B640.,66UH.,66UJ.,66UL.,1657.,66UI.,66UK,K5A2.,K5A20,K5A21,K5A22,K5A23,K5A2z.,K5A2.,J77.,J77Z.,151K.,151J,K5A.,K5Az.,K5A.,K5Az.,2F23.,2F24.,R27.,R270.,R27Z.,2FS.,M2y47,R027.,R0270,R027z.,R027,N331B,N3312,N3313,N3314,N3315,N3316,NyuB0,N3318,N3319,N331A,N331H,N331J,N331K,N331L,N331M,NyuB8,N3302,N3306,N3304,N3370,N3307,N3305,N330D,N3303,N3308,N330C,N3301,N330A,NyuB1.,M61.,66aA.,66aB.,66a9.,66a2.,66a8.,58EG.,66a5.,58EM.,58EA.,585O.,66a6.,66a7.,66a4.,66a3,5800,N330.,N3300,N330B,N330z,NyuB2.,58EV.,N330,C283.,C284.,C285.,C286.,C287.,NyuB3,NyuB4,C28B.,NyuB9.,M651.,M652.,M653.,M654.,M655.,M656.,M657.,M658.,M65Z,N338.,N3380,N3384,N3385.,N338.,M65.,N3381,N3382,N3383,N3386,S3z2.,S3z2.,M62.,M621.,M622.,M623.,M624.,M625.,M626.,M627.,M628.,M62Z,N3310,N3311,N3317,N331C,N331y,N331z,NyuCE,N339.,NyuB5,N338z,N3323,N33zA,N333.,N3330,N3331,N333z,N335.,N3350.,N335,N3321,N3322.,M63.,N332.,N3320,N332z,NyuB6.,N332,N3324,NyuB7,NyuBB,NyuBC.,585P.,58EN.,58EH.,58EB,58000,NyuB.,NyuBA.,58EW</p>
<i>Comorbidities</i>	available	
<i>Other current or recent drug therapies</i>	available	
<i>Use of E+P HRT</i>	available	
<i>Off-label use</i>	<b>Variable used to address off-label use (database):</b>	

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<i>Use for treatment of osteoporosis</i>	available	<p>READ:</p> <p>N331B,N3312,N3313,N3314,N3315,N3316,NyuB0,  N3318,N3319,N331A,N331H,N331J,N331K,N331L,  N331M,NyuB8,N3302,N3306,N3304,N3370,N3307,  N3305,N330D,N3303,N3308,N330C,N3301,N330A,  NyuB1,.M61,.66aA,.66aB,.66a9,.66a2,.66a8,.58EG,.  66a5,.58EM,.58EA,.585O,.66a6,.66a7,.66a4,.66a3,58  00,N330.,N3300,N330B,N330z,NyuB2,.58EV,.N330,  C283.,C284.,C285.,C286.,C287.,NyuB3,NyuB4,C28  B.,NyuB9,.M651,.M652,.M653,.M654,.M655,.M656,  .M657,.M658,.M65Z,N338.,N3380,N3384,N3385,.N  338,.M65.,N3381,N3382,N3383,N3386,S3z2,.S3z2,.  M62.,M621,.M622,.M623,.M624,.M625,.M626,.M6  27,.M628,.M62Z,N3310,N3311,N3317,N331C,N331  y,N331z,NyuCE,N339.,NyuB5,N338z,N3323,N33zA  ,N333.,N3330,N3331,N333z,N335.,N3350,N335,N3  321,N3322,.M63.,N332.,N3320,N332z,NyuB6,.N332  ,N3324,NyuB7,NyuBB,NyuBC,.585P,.58EN,.58EH,.  58EB,58000,NyuB.,NyuBA,.58EW</p>
<i>Use in pre-menopausal women</i>	Inference based on age	
<i>Use in women without a uterus (hysterectomised women)</i>		<p>READ:</p> <p>7E04500,7E05.12,7E04400,7E04700,7E04711,7E04.  11,7E04.12,7E04900,7E04312,1599,7E05300,7E045  12,7E04800,K515.00,7E04A00,685H.11,685H.00,8L  70.00,7E04C00,7E05400,7E04600,7E04511,L39850  0,7F1A000,7E04100,7E05500,7E05y11,9O8W.00,7E  05.11,7E05100,7E04311,7E04G00,7E04E00,7E04F0  0,7E05600,7E05311</p>
<i>Use in males</i>	gender	
<i>Use in women over 75 years old.</i>	Inference based on age	
<i>Use of non-approved dose (i.e. more than one pill per day, divided tablets)</i>	Prescribed dose	

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<i>Use with progestins, additional oestrogens or selective oestrogen receptor modulators (SERMs)</i>	comedication	
<i>Use in women with any of the following contraindicated conditions:</i>		
<i>Known, suspected, or past history of breast cancer.</i>	Comorbidities (In 12 month baseline period)	<p>READ:</p> <p>B340.,B3400,B3401,B340z,B350.,B3500,B3501,B350z,B341.,B342.,B343.,B344.,B345.,B346.,B347.,B34y0,B35z0,BB9J.,B34...,B34y.,B34yz,B34z.,B35...,B35z.,B35zz,BB94.,BB9G.,BB9K.,BB9K0,BB9L.,BB9M.,BBM9.,Byu6.,K31y4,B36.,</p>
<i>Use for prevention of breast cancer.</i>	available	<p>READ:</p> <p>B340.,B3400,B3401,B340z,B350.,B3500,B3501,B350z,B341.,B342.,B343.,B344.,B345.,B346.,B347.,B34y0,B35z0,BB9J.,B34...,B34y.,B34yz,B34z.,B35...,B35z.,B35zz,BB94.,BB9G.,BB9K.,BB9K0,BB9L.,BB9M.,BBM9.,Byu6.,K31y4,B36.,</p>
<i>Hypersensitivity (e.g. anaphylaxis/anaphylactoid reactions, urticaria, drug eruption) to the active substances or to any of the excipients.</i>	Comorbidities, some missing information expected	<p>READ:</p> <p>M280.00; M281.00; M28..00; SN50.00; 14M5.00</p>
<i>History of malignancy potentially associated with oestrogen</i>	Comorbidities	<p>READ:</p> <p>B430200; B832000; B430211; K5A1.; K5A6.; N3323; N33zA; N333.; N3330; N3331</p> <p>N333z</p>



**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<i>Active or past history of venous thromboembolism (deep venous thrombosis, pulmonary embolism, and retinal vein thrombosis); active or past history of arterial thromboembolic disease (e.g., myocardial infarction, stroke); acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal.</i>	Comorbidities and Inference through comedication	<p>READ:</p> <p>J62...,J620.,J6200,J6201,J6202,J6203,J6204,J620z,J60...J600.,J6000,J6001,J6002,J600z,J601.,J6010,J6011,J6012,J601z,J60z.,J61y0,J622.,J625.,J6350,J6351,J6357,J6352,J6353,J6354,J6355,J6330,J635.,J6356,Jyu70,J635X,Jyu76,G65z1,G66.,G667.,G668.,G669.,C13A.,G63y0,G63y1,G6W...,Gyu6G.,G6W.,F4238,F4239,F423A,FyuF6,G921,G81.,F423.,F4230,F423z,J636.,J634.,G6400,G6410,G6X...,Gyu63,G6760,Gyu64,G64z4,G64z.,G64z0,G64z2,G64z3,G664.,G621.,G622.,G623.,G620.,G62.,G62z.,G611.,G612.,G616.,G610.,G61X.,G61X0,G61X1,Gyu6F,G614.,G615.,G613.,G617.,G618.,Gyu62,G619.,G61.,G61z.,G621.,G622.,G623.,G620.,G62.,G62z.,G611.,G612.,G616.,G610.,G61X.,G61X0,G61X1,Gyu6F,G614.,G615.,G613.,G617.,G618.,Gyu62,G619.,G61.,G61z.,G350.,G351.,G353.,Gyu35,G35.,G35X.,Gyu36,0,3233,G300.,G301.,G3010,G3011,G301z,G380.,G302.,G303.,G308.,G30yz,G381.,0,3234,0,3236,G304.,G305.,G306.,G30y2,G382.,G30B.,G309.,G30X.,G30X0,G383.,Gyu34,0,3235,G307.,G3070,G3071,G30y1,G384.,G30.,G30A.,G30y.,G30y0,G30z.,G38.,G38z.,G40.,G400.,G40z.,G401.,G4010,G402.,G4011,G820.,G821.,G822.,G8220,G823.,K1384,G82.,G82y.,Gyu82,G824.,G825.,G826.,G827.,SP08a,G82z.,G82z0,G82z1,G82zz,G783.,G784.,G7840,G7841,G7842,G8010,G8016,G80y0,G80y1,G80y2,G80y3,G80y4,G80y5,G80y6,G80y7,G80y8,G8011,G8012,G8013,G8014,G8015,G8017,G8018,G8019,G801A,G801B,G801C,G801D,Gyu80,SP122,G801E,G801F,G801G,G801.,G801z,G802.,G8020,G80y.,G80y9,G80yz,Gyu81,SP12.,SP120,P121,G80.,G80z.,G80z0,G80z1,G80zz</p>
<i>Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency).</i>	Comorbidities	<p>READ: D30A000; D30A.00</p>
<i>Women of childbearing potential.</i>	based on inference by age	

**Table 4. Feasibility of Study Objectives/Analyses by Country/Database**

<i>Porphyria.</i>	Comorbidities	READ: C371.,C3712,C3713,C3715,C371z,Cyu8H,F3748,Q4 338,C3716
-------------------	---------------	--

**Table 5. ICD-10 to READ Code Translation**

READ CODE	READ TEXT	ICD10 CODE	ICD10 TEXT
J62..	Liver abscess/chr.liver seque.	K750	ABSCESS OF LIVER
J620.	Liver abscess - excl.amoebic	K750	ABSCESS OF LIVER
J6200	Liver abscess + portal pyaemia	K750	ABSCESS OF LIVER
J6201	Liver abscess + cholangitis	K750	ABSCESS OF LIVER
J6202	Liver abscess via hepatic art.	K750	ABSCESS OF LIVER
J6203	Liver abscess via umbilicus	K750	ABSCESS OF LIVER
J6204	Liver abscess-direct extension	K750	ABSCESS OF LIVER
J620z	Liver abscess NOS	K750	ABSCESS OF LIVER
J60..	Acute/subacute liver necrosis	K720	AC AND SUBAC HEP FAILURE
J600.	Acute necrosis of liver	K720	AC AND SUBAC HEP FAILURE
J6000	Acute hepatic failure	K720	AC AND SUBAC HEP FAILURE
J6001	Acute hepatitis-noninfective	K720	AC AND SUBAC HEP FAILURE
J6002	Acute yellow atrophy	K720	AC AND SUBAC HEP FAILURE
J600z	Acute necrosis of liver NOS	K720	AC AND SUBAC HEP FAILURE
J601.	Subacute necrosis of liver	K720	AC AND SUBAC HEP FAILURE
J6010	Subacute hepatic failure	K720	AC AND SUBAC HEP FAILURE
J6011	Subacute hepatitis-noninfect.	K720	AC AND SUBAC HEP FAILURE
J6012	Subacute yellow atrophy	K720	AC AND SUBAC HEP FAILURE
J601z	Subacute necrosis of liver NOS	K720	AC AND SUBAC HEP FAILURE

**Table 5. ICD-10 to READ Code Translation**

J60z.	Acute/subacute liver necr.NOS	K720	AC AND SUBAC HEP FAILURE
J61y0	Chronic yellow liver atrophy	K721	CHRONIC HEPATIC FAILURE
J622.	Hepatic coma	K729	HEPATIC FAILURE UNSP
J625.	[X] Hepatic failure	K729	HEPATIC FAILURE UNSP
J6350	Tox liver dis with cholestasis	K710	TOX LIVER D+CHOLESTAS
J6351	Tox liver dis with hep necros	K711	TOX LIVER D+HEP NECROS
J6357	Acute hepat failure due drugs	K711	TOX LIVER D+HEP NECROS
J6352	Tox liver dis + acut hepatitis	K712	TOX LIVER D+AC HEPATIT
J6353	Tox liver dis + chr pers hepat	K713	TOX LIV D+CHR PERS HEPAT
J6354	Tox liver dis + chr lob hepat	K714	TOX LIV D+CHR LOB HEPAT
J6355	Tox liver dis + chr activ hep	K715	TOX LIV D+CHR ACT HEPAT
J6330	Toxic hepatitis	K716	TOX LIVER D+HEPATIT NEC
J635.	Toxic liver disease	K716	TOX LIVER D+HEPATIT NEC
J6356	Tox liver dis + fibro/cirr liv	K717	TOX LIVER D+FIBROS/CIRRH
Jyu70	[X]Toxc liver dis+o diso/liver	K718	TOX LIVER DIS+O/DIS
J635X	Toxic liver disease,unspec	K719	TOXIC LIVER DIS UNSP
Jyu76	[X]Toxic liver disease,unspec	K719	TOXIC LIVER DIS UNSP
G65z1	Intermittent CVA	I640	STRK N/SPEC AS HM/INFARC
G66..	Stroke/CVA unspecified	I640	STRK N/SPEC AS HM/INFARC
G667.	Left sided CVA	I640	STRK N/SPEC AS HM/INFARC
G668.	Right sided CVA	I640	STRK N/SPEC AS HM/INFARC
G669.	Cere palsy not cong/infant ac	I640	STRK N/SPEC AS HM/INFARC
C13A.	Pituitary apoplexy	I640	STRK N/SPEC AS HM/INFARC
G63y0	Cerebr infct/throm/precere art	I630	CER INFAR-THR PRECER ART
G63y1	Cerebr infct/embol/precere art	I631	CER INFAR-EMB PRECER ART
G6W..	Cer inf,un oc/st precere art	I632	CI-UNSP OC/ST PRECER ART
Gyu6G	[X]Cer inf,un oc/st precere art	I632	CI-UNSP OC/ST PRECER ART
.G6W.	Cer inf,un oc/st precere art	I632	CI-UNSP OC/ST PRECER ART

**Table 5. ICD-10 to READ Code Translation**

G6400	Cerebr infct/throm/cerebrl art	I633	CER INFAR-THROMB CER ART
G6410	Cerebr infct/embol/cerebrl art	I634	CER INFAR-EMBOL CER ART
G6X..	Cereb in/uns oc,stn/cereb a	I635	CI-UNSP OC/STEN CER ART
Gyu63	[X]Cereb in/uns oc,stn/cereb a	I635	CI-UNSP OC/STEN CER ART
G6760	Cere infct/cere vn thrm,nonpyo	I636	CI-CER VEN THR NONPYOG
Gyu64	[X]Other cerebral infarction	I638	OTH CEREBRAL INFARCTION
G64z4	Infarction of basal ganglia	I638	OTH CEREBRAL INFARCTION
G64z.	Cerebral infarction NOS	I639	CEREB INFARCT UNSP
G64z0	Brainstem infarction	I639	CEREB INFARCT UNSP
G64z2	Left sided cerebral infarction	I639	CEREB INFARCT UNSP
G64z3	Right sided cerebral infarct	I639	CEREB INFARCT UNSP
G664.	Cerebellar stroke syndrome	I639	CEREB INFARCT UNSP
G621.	Subdural haemorrhage-nontraum.	I620	AC NONTRAUM SUBDUR HAEM
G622.	Subdural haematoma - nontraum	I620	AC NONTRAUM SUBDUR HAEM
G623.	Subdural haemorrhage NOS	I620	AC NONTRAUM SUBDUR HAEM
G620.	Extradural haemorrh.-nontraum.	I621	NONTRAUM EXTRADUR HAEMRH
G62..	Oth/unspec intracranial bleed	I629	INTRACR HM(NONTRAUM)UNSP
G62z.	Intracranial haemorrhage NOS	I629	INTRACR HM(NONTRAUM)UNSP
G611.	Internal capsule haemorrhage	I610	INTRACER HM-HEM SUBCORT
G612.	Basal nucleus haemorrhage	I610	INTRACER HM-HEM SUBCORT
G616.	External capsule haemorrhage	I610	INTRACER HM-HEM SUBCORT
G610.	Cortical haemorrhage	I611	INTRACER HM-HEMISPH CORT
G61X.	Intracere haem hemisph, unsp	I612	INTRACER HM-HEMISPH UNSP
G61X0	Left side intracereb haem unsp	I612	INTRACER HM-HEMISPH UNSP
G61X1	Right side intracereb haem unsp	I612	INTRACER HM-HEMISPH UNSP
Gyu6F	[X]Intracere haem hemisph, unsp	I612	INTRACER HM-HEMISPH UNSP
G614.	Pontine haemorrhage	I613	INTRACEREB HAEM-BRN STEM
G615.	Bulbar haemorrhage	I613	INTRACEREB HAEM-BRN STEM
G613.	Cerebellar haemorrhage	I614	INTRACEREB HAEM-CEREBELL

**Table 5. ICD-10 to READ Code Translation**

G617.	Intracereb haem,intraventriculr	I615	INTRACEREB HAEM INTRAVEN
G618.	Intracerebrl haem,multip local	I616	INTRACEREB HAEM MULT LOC
Gyu62	[X]Oth intracerebrl h'morrhage	I618	OTH INTRACEREB HAEMRH
G619.	Lobar cerebral haemorrhage	I618	OTH INTRACEREB HAEMRH
G61..	Intracerebral haemorrhage	I619	INTRACEREB HAEMRH UNSP
G61z.	Intracerebral haemorrhage NOS	I619	INTRACEREB HAEMRH UNSP
G621.	Subdural haemorrhage-nontraum.	I620	AC NONTRAUM SUBDUR HAEM
G622.	Subdural haematoma - nontraum	I620	AC NONTRAUM SUBDUR HAEM
G623.	Subdural haemorrhage NOS	I620	AC NONTRAUM SUBDUR HAEM
G620.	Extradural haemorrh.-nontraum.	I621	NONTRAUM EXTRADUR HAEMRH
G62..	Oth/unspec intracranial bleed	I629	INTRACR HM(NONTRAUM)UNSP
G62z.	Intracranial haemorrhage NOS	I629	INTRACR HM(NONTRAUM)UNSP
G611.	Internal capsule haemorrhage	I610	INTRACER HM-HEM SUBCORT
G612.	Basal nucleus haemorrhage	I610	INTRACER HM-HEM SUBCORT
G616.	External capsule haemorrhage	I610	INTRACER HM-HEM SUBCORT
G610.	Cortical haemorrhage	I611	INTRACER HM-HEMISP H CORT
G61X.	Intracereb haem hemisph, unsp	I612	INTRACER HM-HEMISP H UNSP
G61X0	Left side intracereb haem unsp	I612	INTRACER HM-HEMISP H UNSP
G61X1	Right side intracereb haem unsp	I612	INTRACER HM-HEMISP H UNSP
Gyu6F	[X]Intracereb haem hemisph, unsp	I612	INTRACER HM-HEMISP H UNSP
G614.	Pontine haemorrhage	I613	INTRACEREB HAEM-BRN STEM
G615.	Bulbar haemorrhage	I613	INTRACEREB HAEM-BRN STEM
G613.	Cerebellar haemorrhage	I614	INTRACEREB HAEM-CEREBELL
G617.	Intracereb haem,intraventriculr	I615	INTRACEREB HAEM INTRAVEN
G618.	Intracerebrl haem,multip local	I616	INTRACEREB HAEM MULT LOC
Gyu62	[X]Oth intracerebrl h'morrhage	I618	OTH INTRACEREB HAEMRH
G619.	Lobar cerebral haemorrhage	I618	OTH INTRACEREB HAEMRH
G61..	Intracerebral haemorrhage	I619	INTRACEREB HAEMRH UNSP
G61z.	Intracerebral haemorrhage NOS	I619	INTRACEREB HAEMRH UNSP

**Table 5. ICD-10 to READ Code Translation**

G350.	Subsqnt myocrd infarc/ant wall	I220	SUBSEQUENT MI ANT WALL
G351.	Subsqnt myocrd infarc/inf wall	I221	SUBSEQUENT MI INFER WALL
G353.	Subseq myo infarct other sites	I228	SUBSEQUENT MI OTH SITES
Gyu35	[X]Subseq myocard inf oth site	I228	SUBSEQUENT MI OTH SITES
G35..	Subseqnt myocardial infarction	I229	SUBSEQUENT MI UNSP SITE
G35X.	Subseq MI of unspec site	I229	SUBSEQUENT MI UNSP SITE
Gyu36	[X]Subseq MI of unspec site	I229	SUBSEQUENT MI UNSP SITE
0.3233	ECG: antero-septal infarct.	I210	AC TRANSMUR MI ANT WALL
G300.	Acute anterolateral infarction	I210	AC TRANSMUR MI ANT WALL
G301.	Anterior myocard. infarct OS	I210	AC TRANSMUR MI ANT WALL
G3010	Acute anteroapical infarction	I210	AC TRANSMUR MI ANT WALL
G3011	Acute anteroseptal infarction	I210	AC TRANSMUR MI ANT WALL
G301z	Anterior myocard.infarct NOS	I210	AC TRANSMUR MI ANT WALL
G380.	Postop transm MI inf wall	I210	AC TRANSMUR MI ANT WALL
G302.	Acute inferolateral infarction	I211	AC TRANSMUR MI INF WALL
G303.	Acute inferoposterior infarct	I211	AC TRANSMUR MI INF WALL
G308.	Inferior myocard. infarct NOS	I211	AC TRANSMUR MI INF WALL
G30yz	Other acute myocardial inf.NOS	I211	AC TRANSMUR MI INF WALL
G381.	Postop transm MI inferior wall	I211	AC TRANSMUR MI INF WALL
0.3234	ECG:posterior/inferior infarct	I212	AC TRANSMUR MI OTH SITES
0.3236	ECG: lateral infarction	I212	AC TRANSMUR MI OTH SITES
G304.	Posterior myocard.infarct NOS	I212	AC TRANSMUR MI OTH SITES
G305.	Lateral myocardial infarct NOS	I212	AC TRANSMUR MI OTH SITES
G306.	True posterior myocard.infarct	I212	AC TRANSMUR MI OTH SITES
G30y2	Acute septal infarction	I212	AC TRANSMUR MI OTH SITES
G382.	Postop transm MI other sites	I212	AC TRANSMUR MI OTH SITES
G30B.	Acute posterol myocard infarct	I212	AC TRANSMUR MI OTH SITES
G309.	Acute Q-wave infarct	I213	AC TRANSMUR MI UNSP SITE
G30X.	Ac transm MI unspec site	I213	AC TRANSMUR MI UNSP SITE

**Table 5. ICD-10 to READ Code Translation**

G30X0	Acute ST segment elevation mi	I213	AC TRANSMUR MI UNSP SITE
G383.	Postop transm MI unspec site	I213	AC TRANSMUR MI UNSP SITE
Gyu34	[X]Ac transmur MI unspec site	I213	AC TRANSMUR MI UNSP SITE
0.3235	ECG: subendocardial infarct	I214	AC SUBENDOCARD MI
G307.	Acute subendocardial infarct	I214	AC SUBENDOCARD MI
G3070	Acute non-Q wave infarction	I214	AC SUBENDOCARD MI
G3071	Acute non-ST seg elevation mi	I214	AC SUBENDOCARD MI
G30y1	Acute papillary muscle infarct	I214	AC SUBENDOCARD MI
G384.	Postop subendocardial MI	I214	AC SUBENDOCARD MI
G30..	Acute myocardial infarction	I219	AC MYOCARD INFARCT UNSP
G30A.	Mural thrombosis	I219	AC MYOCARD INFARCT UNSP
G30y.	Other acute myocardial infarct	I219	AC MYOCARD INFARCT UNSP
G30y0	Acute atrial infarction	I219	AC MYOCARD INFARCT UNSP
G30z.	Acute myocardial infarct. NOS	I219	AC MYOCARD INFARCT UNSP
G38..	Postoperative MI	I219	AC MYOCARD INFARCT UNSP
G38z.	Postop MI,unspec	I219	AC MYOCARD INFARCT UNSP
G40..	Acute pulmonary heart disease	I260	PULM EMBOL+AC COR PULMON
G400.	Acute cor pulmonale	I260	PULM EMBOL+AC COR PULMON
G40z.	Acute pulmonary heart dis. NOS	I260	PULM EMBOL+AC COR PULMON
G401.	Pulmonary embolism	I269	PULM EMB WO AC COR PULM
G4010	Post operative PE	I269	PULM EMB WO AC COR PULM
G402.	Pulmonary infarct	I269	PULM EMB WO AC COR PULM
G4011	Recurrent pulmonary embolism	I269	PULM EMB WO AC COR PULM
G820.	Budd-Chiari syndrome (hepat.v)	I820	BUDD CHIARI SYNDROME
G821.	Thrombophlebitis migrans	I821	THROMBOPHLEBITIS MIGRANS
G822.	Embolus/thrombosis-vena cava	I822	EMBOL & THROMB VENA CAVA
G8220	Thrombosis inferior vena cava	I822	EMBOL & THROMB VENA CAVA
G823.	Embolus/thrombosis-renal vein	I823	EMBOL & THROMB REN VEIN
K1384	Renal artery stent thrombosis	I823	EMBOL & THROMB REN VEIN

**Table 5. ICD-10 to READ Code Translation**

G82..	Other venous embolus/thrombus	I828	EMBOL/THROMB O/SPEC VEIN
G82y.	Other embolus/thrombosis	I828	EMBOL/THROMB O/SPEC VEIN
Gyu82	[X]Embolsm+thrombsis/o spc vns	I828	EMBOL/THROMB O/SPEC VEIN
G824.	Axillary vein thrombosis	I828	EMBOL/THROMB O/SPEC VEIN
G825.	Thrombosis of subclavian vein	I828	EMBOL/THROMB O/SPEC VEIN
G826.	Thromb internal jugular vein	I828	EMBOL/THROMB O/SPEC VEIN
G827.	Thromb external jugular vein	I828	EMBOL/THROMB O/SPEC VEIN
SP08a	Thromb vein transplantd kidney	I828	EMBOL/THROMB O/SPEC VEIN
G82z.	Embolus/thrombosis NOS	I829	EMBOL & THROMB UNSP VEIN
G82z0	Embolus of vein NOS	I829	EMBOL & THROMB UNSP VEIN
G82z1	Thrombosis of vein NOS	I829	EMBOL & THROMB UNSP VEIN
G82zz	Embolus/thrombosis NOS	I829	EMBOL & THROMB UNSP VEIN
G783.	Occlusion artery of upper limb	I829	EMBOL & THROMB UNSP VEIN
G784.	Occlusion of artery lower limb	I829	EMBOL & THROMB UNSP VEIN
G7840	Occlusn dorsalis pedis artery	I829	EMBOL & THROMB UNSP VEIN
G7841	Occlusn anterior tibial artery	I829	EMBOL & THROMB UNSP VEIN
G7842	Occlusn posterior tibial artry	I829	EMBOL & THROMB UNSP VEIN
G8010	Phlebitis of femoral vein	I801	PHLEB/THROMBOPHL FEM VN
G8016	Thrombophlebitis femoral vein	I801	PHLEB/THROMBOPHL FEM VN
G80y0	Phlebitis of common iliac vein	I801	PHLEB/THROMBOPHL FEM VN
G80y1	Phlebitis of intern.ilic vein	I801	PHLEB/THROMBOPHL FEM VN
G80y2	Phlebitis of extern.ilic vein	I801	PHLEB/THROMBOPHL FEM VN
G80y3	Phlebitis of iliac vein unspec	I801	PHLEB/THROMBOPHL FEM VN
G80y4	Thrombophleb.common iliac vein	I801	PHLEB/THROMBOPHL FEM VN
G80y5	Thrombophleb.intern.ilic vein	I801	PHLEB/THROMBOPHL FEM VN
G80y6	Thrombophleb.extern iliac vein	I801	PHLEB/THROMBOPHL FEM VN
G80y7	Thrombophleb.ilic vein unspec	I801	PHLEB/THROMBOPHL FEM VN
G80y8	Phlebit./thromb.ilic vein NOS	I801	PHLEB/THROMBOPHL FEM VN
G8011	Phlebitis of popliteal vein	I802	PHLEB/THR-PH O/DP VS LEG
G8012	Phlebitis of ant.tibial vein	I802	PHLEB/THR-PH O/DP VS LEG



**Table 5. ICD-10 to READ Code Translation**

G8013	Phlebitis dorsalis pedis vein	I802	PHLEB/THR-PH O/DP VS LEG
G8014	Phlebitis of post.tibial vein	I802	PHLEB/THR-PH O/DP VS LEG
G8015	Deep vein phlebitis leg unsp.	I802	PHLEB/THR-PH O/DP VS LEG
G8017	Thrombophleb.popliteal vein	I802	PHLEB/THR-PH O/DP VS LEG
G8018	Thrombophleb.ant.tibial vein	I802	PHLEB/THR-PH O/DP VS LEG
G8019	Thrombophleb.dors.pedis vein	I802	PHLEB/THR-PH O/DP VS LEG
G801A	Thrombophleb.post.tibial vein	I802	PHLEB/THR-PH O/DP VS LEG
G801B	Deep vein thrombophleg unsp.	I802	PHLEB/THR-PH O/DP VS LEG
G801C	DVT of leg related air travel	I802	PHLEB/THR-PH O/DP VS LEG
G801D	Deep vein thromb lower limb	I802	PHLEB/THR-PH O/DP VS LEG
Gyu80	[X]Phlb+thrmphlb/o dp vs/l ex	I802	PHLEB/THR-PH O/DP VS LEG
SP122	Post operative DVT	I802	PHLEB/THR-PH O/DP VS LEG
G801E	DVT leg related intra drug use	I802	PHLEB/THR-PH O/DP VS LEG
G801F	Deep vein thromb peroneal vein	I802	PHLEB/THR-PH O/DP VS LEG
G801G	Recurrent deep vein thrombosis	I802	PHLEB/THR-PH O/DP VS LEG
G801.	Deep phlebitis/thrombophl. leg	I803	PHLEB/THR/PHLEB LEG UNSP
G801z	Deep phlebit/thrombophleg NOS	I803	PHLEB/THR/PHLEB LEG UNSP
G802.	Phlebitis/thrombophlegleg NOS	I803	PHLEB/THR/PHLEB LEG UNSP
G8020	Thrombosis of vein of leg	I803	PHLEB/THR/PHLEB LEG UNSP
G80y.	Other phlebitis/thrombophleg.	I808	PHLEB/THROMBOPHLEB O/ST
G80y9	Thrombophlebit.breast-Mondor's	I808	PHLEB/THROMBOPHLEB O/ST
G80yz	Other phlebitis/thrombophleg.NOS	I808	PHLEB/THROMBOPHLEB O/ST
Gyu81	[X]Phleb+thombophlebit/o sites	I808	PHLEB/THROMBOPHLEB O/ST
SP12.	Periph.vasc.complic.of care	I808	PHLEB/THROMBOPHLEB O/ST
SP120	Phlebitis complication of care	I808	PHLEB/THROMBOPHLEB O/ST
SP121	Thrombophlebitis compl.of care	I808	PHLEB/THROMBOPHLEB O/ST
G80..	Phlebitis and thrombophlebitis	I809	PHLEB/THROMBOPHL UNSP ST
G80z.	Phlebitis/thrombophlebitis NOS	I809	PHLEB/THROMBOPHL UNSP ST
G80z0	Phlebitis NOS	I809	PHLEB/THROMBOPHL UNSP ST
G80z1	Thrombophlebitis NOS	I809	PHLEB/THROMBOPHL UNSP ST
G80zz	Phlebitis/thrombophlebitis NOS	I809	PHLEB/THROMBOPHL UNSP ST

**Table 5. ICD-10 to READ Code Translation**

C371.	Porphyria metabolism disorders	E802	OTHER PORPHYRIA
C3712	Acute intermittent porphyria	E802	OTHER PORPHYRIA
C3713	Protocoproporphyria	E802	OTHER PORPHYRIA
C3715	Coproporphyria	E802	OTHER PORPHYRIA
C371z	Porphyria NOS	E802	OTHER PORPHYRIA
Cyu8H	[X]Other porphyria	E802	OTHER PORPHYRIA
F3748	Polyneuropathy in porphyria	E802	OTHER PORPHYRIA
Q4338	Neonatal jaundice+porphyria	E802	OTHER PORPHYRIA
C3716	Pseudoporphyria	E802	OTHER PORPHYRIA
K5A1.	Postmenopausal bleeding	N950	POSTMENOPAUSAL BLEEDING
K5A6.	Perimenopausal menorrhagia	N950	POSTMENOPAUSAL BLEEDING
0.1512	Menopause	N951	MENOPAUS/FM CLIMAC STATE
.66U3	Menopause symptoms present	N951	MENOPAUS/FM CLIMAC STATE
.66U7	HRT started	N951	MENOPAUS/FM CLIMAC STATE
.66U9	HRT changed	N951	MENOPAUS/FM CLIMAC STATE
.66UB	HRT: unopposed oestrogen	N951	MENOPAUS/FM CLIMAC STATE
.66UC	HRT: combined oestrogen/progest	N951	MENOPAUS/FM CLIMAC STATE
.8B64	Hormone replacement therapy	N951	MENOPAUS/FM CLIMAC STATE
8B640	HRT ongoing treatment	N951	MENOPAUS/FM CLIMAC STATE
.66UH	HRT bleed pattern - normal	N951	MENOPAUS/FM CLIMAC STATE
.66UJ	HRT bleed pattern - not relevant	N951	MENOPAUS/FM CLIMAC STATE
.66UL	Years on HRT	N951	MENOPAUS/FM CLIMAC STATE
0.1657	Hot flushes	N951	MENOPAUS/FM CLIMAC STATE
.66UI	HRT bleed pattern - abnormal	N951	MENOPAUS/FM CLIMAC STATE
.66UK	HRT bleed pattern - no bleeding	N951	MENOPAUS/FM CLIMAC STATE
K5A2.	Menopausal/female climacteric state	N951	MENOPAUS/FM CLIMAC STATE
K5A20	Menopausal flushing	N951	MENOPAUS/FM CLIMAC STATE
K5A21	Menopausal sleeplessness	N951	MENOPAUS/FM CLIMAC STATE
K5A22	Menopausal headache	N951	MENOPAUS/FM CLIMAC STATE

**Table 5. ICD-10 to READ Code Translation**

K5A23	Menopausal concentration lack	N951	MENOPAUS/FM CLIMAC STATE
K5A2z	Menopausal symptoms NOS	N951	MENOPAUS/FM CLIMAC STATE
K5A3.	Postmenop. atrophic vaginitis	N952	POSTMENOPAUS ATROPH VAG
K5A30	Atrophy of vagina	N952	POSTMENOPAUS ATROPH VAG
K5A4.	Artificial menopause state	N953	STATES ASS+ARTIFIC MENOP
K5Ay.	Other meno/postmenopaus.state	N958	O/SPEC MENOP/PERIMEN DIS
Kyu9F	[X]O spc meno+perimenopausal d	N958	O/SPEC MENOP/PERIMEN DIS
K5A5.	Perimenopaus atroph vaginitis	N958	O/SPEC MENOP/PERIMEN DIS
K5A..	Menopausal/postmenopausal dis.	N959	MENOP/PERIMEN DIS UNSP
K5Az.	Menopause/postmenopause NOS	N959	MENOP/PERIMEN DIS UNSP
B340.	Malig neop nipple/areola (f)	C500	CA NIPPLE & AREOLA
B3400	Malig neop nipple of breast(f)	C500	CA NIPPLE & AREOLA
B3401	Malig neop areola of breast(f)	C500	CA NIPPLE & AREOLA
B340z	Malig neop nippl/areol (f) NOS	C500	CA NIPPLE & AREOLA
B350.	Malig neop nipple/areola (m)	C500	CA NIPPLE & AREOLA
B3500	Malig neop nipple male breast	C500	CA NIPPLE & AREOLA
B3501	Malig neop areola male breast	C500	CA NIPPLE & AREOLA
B350z	Malig neop nippl/areol (m) NOS	C500	CA NIPPLE & AREOLA
B341.	Malig neop cent part breast(f)	C501	CA CENTRAL PORT BREAST
B342.	Malig neop upp-inner quad (f)	C502	CA UPP INNER QUAD BREAST
B343.	Malig neop low-inner quad (f)	C503	CA LOW INNER QUAD BREAST
B344.	Malig neop upp-outer quad (f)	C504	CA UPP OUTER QUAD BREAST
B345.	Malig neop low-outer quad (f)	C505	CA LOW OUTER QUAD BREAST
B346.	Malig neop axillary tail (f)	C506	CA AXILLARY TAIL BREAST
B347.	Mal neopl, overlapping breast	C508	CA OVERL LES BREAST
B34y0	Malig neop ectopic breast (f)	C508	CA OVERL LES BREAST
B35z0	Malig neop ectopic breast (m)	C508	CA OVERL LES BREAST
BB9J.	[M]Paget's disease, mammary	C508	CA OVERL LES BREAST
B34..	Malig neop female breast (f)	C509	CA OF BREAST UNSP
B34y.	Malig neop oth site breast (f)	C509	CA OF BREAST UNSP

**Table 5. ICD-10 to READ Code Translation**

B34yz	Malig neop oth breast (f) NOS	C509	CA OF BREAST UNSP
B34z.	Malig neop female breast NOS	C509	CA OF BREAST UNSP
B35..	Malig neop male breast (m)	C509	CA OF BREAST UNSP
B35z.	Malig neop oth site breast (m)	C509	CA OF BREAST UNSP
B35zz	Malig neop male breast NOS	C509	CA OF BREAST UNSP
BB94.	[M]Juvenile breast carcinoma	C509	CA OF BREAST UNSP
BB9G.	[M]Infiltrating ductular ca.	C509	CA OF BREAST UNSP
BB9K.	[M]Paget+infiltrating breast duct ca	C509	CA OF BREAST UNSP
BB9K0	[M]Pagets+intraductal carcinoma breast	C509	CA OF BREAST UNSP
BB9L.	[M]Paget's disease of the breast	C509	CA OF BREAST UNSP
BB9M.	[M]Intracystic carcinoma NOS	C509	CA OF BREAST UNSP
BBM9.	[M]Cystosarcoma phyllodes, mal	C509	CA OF BREAST UNSP
Byu6.	[X]Malignant neoplasm/breast	C509	CA OF BREAST UNSP
K31y4	Microcalcifications of breast	C509	CA OF BREAST UNSP
B36..	Loc recur malign tumour breast	C509	CA OF BREAST UNSP
B431.	Malig neop isthmus of uterus	C540	CA OF ISTHMUS UTERI
B4310	Malig neop low uterine segment	C540	CA OF ISTHMUS UTERI
B431z	Malig neop isthmus uterus NOS	C540	CA OF ISTHMUS UTERI
B4302	Malig neop endometrium corpus uteri	C541	CA OF ENDOMETRIUM
BBL0.	[M]Endometrial stromal sarcoma	C541	CA OF ENDOMETRIUM
B4303	Malig neop myometrium corpus uteri	C542	CA OF MYOMETRIUM
B4301	Malig neop fundus corpus uteri	C543	CA OF FUNDUS UTERI
B432.	Mal neop, overlap lesion corpus uteri	C548	CA OVERLAP LESION CORPUS UTERI
B43..	Malig neop body of uterus	C549	CA CORPUS UTERI UNSP
B430.	Malig neop corpus uteri, ex isthmus	C549	CA CORPUS UTERI UNSP
B4300	Malig neop cornu corpus uteri	C549	CA CORPUS UTERI UNSP
B430z	Malig neop corpus uteri NOS	C549	CA CORPUS UTERI UNSP
B43y.	Malig neop other uterine body	C549	CA CORPUS UTERI UNSP
B43z.	Malig neop body of uterus NOS	C549	CA CORPUS UTERI UNSP
BBL5.	[M]Mullerian mixed tumour	C549	CA CORPUS UTERI UNSP
B440.	Malig neop ovary	C560	CA OF OVARY

**Table 5. ICD-10 to READ Code Translation**

BBC4.	[M]Granulosa cell tumour,malig	C560	CA OF OVARY
BBM01	[M]Brenner tumour, malignant	C560	CA OF OVARY
BBQ9.	[M]Dermoid cyst+malig.transfor	C560	CA OF OVARY
D2120	Anaemia in ovarian carcinoma	C560	CA OF OVARY
B44..	Malig neop ovary/uterine adnex	C578	CA OVERL LES FEM GEN ORG
B45X.	Mal neo/olap les/fm gen org	C578	CA OVERL LES FEM GEN ORG
Byu72	[X]Mal neo/olap les/fm gen org	C578	CA OVERL LES FEM GEN ORG
B45..	Malig neop oth female genital	C579	CA FEM GEN ORGAN UNSP
B45z.	Malig neop female genital NOS	C579	CA FEM GEN ORGAN UNSP
Byu7.	[X]Mal neoplasm/fem gen organs	C579	CA FEM GEN ORGAN UNSP
Byu73	[X]Mal neo/fem gen organ,unspc	C579	CA FEM GEN ORGAN UNSP
B8337	Vaginal intraepithel neopl 1	C579	CA FEM GEN ORGAN UNSP
B8338	Vag intraepith neop 2	C579	CA FEM GEN ORGAN UNSP
B8339	Vag intraepith neop 3	C579	CA FEM GEN ORGAN UNSP
.1512	Menopause	N951	MENOPAUS/FM CLIMAC STATE
.66U3	Menopause symptoms present	N951	MENOPAUS/FM CLIMAC STATE
.66U7	HRT started	N951	MENOPAUS/FM CLIMAC STATE
.66U9	HRT changed	N951	MENOPAUS/FM CLIMAC STATE
.66UB	HRT: unopposed oestrogen	N951	MENOPAUS/FM CLIMAC STATE
.66UC	HRT: combined oestrog/progest	N951	MENOPAUS/FM CLIMAC STATE
.8B64	Hormone replacement therapy	N951	MENOPAUS/FM CLIMAC STATE
.J773	Climateric symptoms	N951	MENOPAUS/FM CLIMAC STATE
8B640	HRT ongoing treatment	N951	MENOPAUS/FM CLIMAC STATE
.66UH	HRT bleed pattern - normal	N951	MENOPAUS/FM CLIMAC STATE
.66UJ	HRT bleed patrn - not relevnt	N951	MENOPAUS/FM CLIMAC STATE
.66UL	Years on HRT	N951	MENOPAUS/FM CLIMAC STATE
.1657	Hot flushes	N951	MENOPAUS/FM CLIMAC STATE
.66UI	HRT bleed pattern - abnormal	N951	MENOPAUS/FM CLIMAC STATE
.66UK	HRT bleed patrn - no bleeding	N951	MENOPAUS/FM CLIMAC STATE
K5A2.	Menopaus./female climact.state	N951	MENOPAUS/FM CLIMAC STATE

**Table 5. ICD-10 to READ Code Translation**

K5A20	Menopausal flushing	N951	MENOPAUS/FM CLIMAC STATE
K5A21	Menopausal sleeplessness	N951	MENOPAUS/FM CLIMAC STATE
K5A22	Menopausal headache	N951	MENOPAUS/FM CLIMAC STATE
K5A23	Menopausal concentration lack	N951	MENOPAUS/FM CLIMAC STATE
K5A2z	Menopausal symptoms NOS	N951	MENOPAUS/FM CLIMAC STATE
.K5A2	Menopaus./female climact.state	N951	MENOPAUS/FM CLIMAC STATE
.J77.	Menopausal/postmenopausal dis.	N959	MENOP/PERIMEN DIS UNSP
.J77Z	Meno/postmenopausal dis. NOS	N959	MENOP/PERIMEN DIS UNSP
.151K	Postmenopausal state	N959	MENOP/PERIMEN DIS UNSP
.151J	Premenopausal state	N959	MENOP/PERIMEN DIS UNSP
K5A..	Menopausal/postmenopausal dis.	N959	MENOP/PERIMEN DIS UNSP
K5Az.	Menopause/postmenopause NOS	N959	MENOP/PERIMEN DIS UNSP
.K5A.	Menopausal/postmenopausal dis.	N959	MENOP/PERIMEN DIS UNSP
.K5Az	Menopause/postmenopause NOS	N959	MENOP/PERIMEN DIS UNSP
.2F23	O/E - petechiae present	R233	SPONTANEOUS ECCHYMOSES
.2F24	O/E - ecchymoses present	R233	SPONTANEOUS ECCHYMOSES
.R27.	Ecchymoses, spontaneous [D]	R233	SPONTANEOUS ECCHYMOSES
.R270	Petechiae [D]	R233	SPONTANEOUS ECCHYMOSES
.R27Z	Ecchymoses, spontaneous NOS[D]	R233	SPONTANEOUS ECCHYMOSES
.2FS.	Petechiae	R233	SPONTANEOUS ECCHYMOSES
M2y47	Black heel	R233	SPONTANEOUS ECCHYMOSES
R027.	[D]Spontaneous ecchymoses	R233	SPONTANEOUS ECCHYMOSES
R0270	[D]Petechiae	R233	SPONTANEOUS ECCHYMOSES
R027z	[D]Spontaneous ecchymoses NOS	R233	SPONTANEOUS ECCHYMOSES
.R027	[D]Spontaneous ecchymoses	R233	SPONTANEOUS ECCHYMOSES
N331B	Postmenop osteopor+path fract	M800	POSTMEN OSTEOP+PATH FRAC
N3312	Postmenop osteopor+path frct	M801	POSTMEN OSTEOP+PATH FRAC
N3313	Osteopor of disuse + path frct	M802	OSTEOP DISUSE+PATH FRAC
N3314	Postmenop osteopor+path frct	M803	P/SG MALAB OSTEOP+PTH FR
N3315	Drug-ind osteopor + path fract	M804	DRG IND OSTEOP+PATH FRAC

**Table 5. ICD-10 to READ Code Translation**

N3316	Idiopath osteopor + path fract	M805	IDIOP OSTEOPOR+PATH FRAC
NyuB0	[X]Oth osteoporosis+patholog #	M808	O/OSTEOPOR+PATH FRAC
N3318	Osteopor path # lumb vertebrae	M809	UNSP OSTEOPOR+PATH FRAC
N3319	Osteopor path # thor vertebrae	M809	UNSP OSTEOPOR+PATH FRAC
N331A	Osteopor path # cerv vertebrae	M809	UNSP OSTEOPOR+PATH FRAC
N331H	Collap cerv vert due to osteop	M809	UNSP OSTEOPOR+PATH FRAC
N331J	Collap lumb vert due to osteo	M809	UNSP OSTEOPOR+PATH FRAC
N331K	Coll thorac vert due osteopor	M809	UNSP OSTEOPOR+PATH FRAC
N331L	Collap vert due osteopor NOS	M809	UNSP OSTEOPOR+PATH FRAC
N331M	Fragility # unsp osteoporosis	M809	UNSP OSTEOPOR+PATH FRAC
NyuB8	[X]Unsp osteopor + pathol frac	M809	UNSP OSTEOPOR+PATH FRAC
N3302	Postmenopausal osteoporosis	M810	POSTMENOPAU OSTEOPOR
N3306	Postoophorectomy osteoporosis	M811	POSTOOPHORECT OSTEOPOR
N3304	Dissuse osteoporosis	M812	OSTEOPOROSIS OF DISUSE
N3370	Disuse atrophy of bone	M812	OSTEOPOROSIS OF DISUSE
N3307	Postsurg malabsorp osteoporos	M813	POSTSURG MALABS OSTEOPOR
N3305	Drug-induced osteoporosis	M814	DRUG IND CD OSTEOPOR
N330D	Osteoporos due corticosteroid	M814	DRUG IND CD OSTEOPOR
N3303	Idiopathic osteoporosis	M815	IDIOPATHIC OSTEOPOROSIS
N3308	Local osteoporosis - Lequesne	M816	LOCAL OSTEOPOR
N330C	Osteoporosis localized spine	M816	LOCAL OSTEOPOR
N3301	Senile osteoporosis	M818	OTHER OSTEOPOROSIS
N330A	Osteoporosis in endocr disord	M818	OTHER OSTEOPOROSIS
NyuB1	[X]Other osteoporosis	M818	OTHER OSTEOPOROSIS
.M61.	Osteoporosis	M819	OSTEOPOROSIS UNSP
.66aA	Osteoporosis-treatmnt response	M819	OSTEOPOROSIS UNSP
.66aB	Osteoporosis-no treat response	M819	OSTEOPOROSIS UNSP
.66a9	Osteoporosis-falls prevention	M819	OSTEOPOROSIS UNSP
.66a2	Osteoporosis treatment started	M819	OSTEOPOROSIS UNSP
.66a8	Osteoporosis - exercise advice	M819	OSTEOPOROSIS UNSP
.58EG	Hip DXA result osteoporotic	M819	OSTEOPOROSIS UNSP

**Table 5. ICD-10 to READ Code Translation**

.66a5	Osteoporosis - no treatment	M819	OSTEOPOROSIS UNSP
.58EM	Lumbar DXA result osteoporotic	M819	OSTEOPOROSIS UNSP
.58EA	Heel DXA result osteoporotic	M819	OSTEOPOROSIS UNSP
.585O	QUS heel - result osteoporotic	M819	OSTEOPOROSIS UNSP
.66a6	Osteoporosis - dietary advice	M819	OSTEOPOROSIS UNSP
.66a7	Osteoporosis - diet assessment	M819	OSTEOPOROSIS UNSP
.66a4	Osteoporosis treatment changed	M819	OSTEOPOROSIS UNSP
.66a3	Osteoporosis treatment stopped	M819	OSTEOPOROSIS UNSP
5800	Forearm DXA res osteoporotic	M819	OSTEOPOROSIS UNSP
N330.	Osteoporosis	M819	OSTEOPOROSIS UNSP
N3300	Osteoporosis, unspecified	M819	OSTEOPOROSIS UNSP
N330B	Vertebral osteoporosis	M819	OSTEOPOROSIS UNSP
N330z	Osteoporosis NOS	M819	OSTEOPOROSIS UNSP
NyuB2	[X]Osteoporosis/oth disorders CE	M819	OSTEOPOROSIS UNSP
.58EV	Femor nec DEXA scan osteoporot	M819	OSTEOPOROSIS UNSP
.N330	Osteoporosis	M819	OSTEOPOROSIS UNSP
C283.	Puerperal osteomalacia	M830	PUERPERAL OSTEOMALACIA
C284.	Senile osteomalacia	M831	SENILE OSTEOMALACIA
C285.	Adult osteomalac due malabsorp	M832	ADLT OSTEOMALAC-MALABS
C286.	Adult osteomalacia due malnutr	M833	ADLT OSTEOMALAC-MALNUT
C287.	Aluminium bone disease	M834	ALUMINIUM BONE DISEASE
NyuB3	[X]O drug-indc osteomalac/adlt	M835	O/DRG IND OSTEOMAL-ADLT
NyuB4	[X]Other adult osteomalacia	M838	OTHER ADULT OSTEOMALACIA
C28B.	Aluminium-related osteomalacia	M838	OTHER ADULT OSTEOMALACIA
NyuB9	[X]Adult osteomalacia, unspec	M839	ADULT OSTEOMALACIA UNSP
.M651	Multiple fracture malunion	M840	MALUNION OF FRACTURE
.M652	Fracture malunion - shoulder	M840	MALUNION OF FRACTURE
.M653	Fracture malunion - upper arm	M840	MALUNION OF FRACTURE
.M654	Fracture malunion - fore arm	M840	MALUNION OF FRACTURE
.M655	Fracture malunion - hand	M840	MALUNION OF FRACTURE
.M656	Fracture malunion-pelvis/thigh	M840	MALUNION OF FRACTURE



**Table 5. ICD-10 to READ Code Translation**

.M657	Fracture malunion - lower leg	M840	MALUNION OF FRACTURE
.M658	Fracture malunion - ankle/foot	M840	MALUNION OF FRACTURE
.M65Z	Fracture malunion - NOS	M840	MALUNION OF FRACTURE
N338.	Malunion/nonunion of fracture	M840	MALUNION OF FRACTURE
N3380	Malunion of fracture	M840	MALUNION OF FRACTURE
N3384	Angular mal-union of fracture	M840	MALUNION OF FRACTURE
N3385	Rotational mal-union of #	M840	MALUNION OF FRACTURE
.N338	Malunion/nonunion of fracture	M840	MALUNION OF FRACTURE
.M65.	Malunion/nonunion of fracture	M841	NONUNION FRAC-PSEUDARTH
N3381	Pseudoarthrosis-fract.nonunion	M841	NONUNION FRAC-PSEUDARTH
N3382	Hypertrophic non-union of #	M841	NONUNION FRAC-PSEUDARTH
N3383	Atrophic non-union of fracture	M841	NONUNION FRAC-PSEUDARTH
N3386	Delayed union of fracture	M842	DELAYED UNION OF FRAC
S3z2.	Stress fracture	M843	STRESS FRACTURE NEC
.S3z2	Stress fracture	M843	STRESS FRACTURE NEC
.M62.	Pathological fracture	M844	PATHOLOGICAL FRAC NEC
.M621	Path.fracture - multiple	M844	PATHOLOGICAL FRAC NEC
.M622	Path.fracture - shoulder	M844	PATHOLOGICAL FRAC NEC
.M623	Path.fracture - upper arm	M844	PATHOLOGICAL FRAC NEC
.M624	Path.fracture - fore arm	M844	PATHOLOGICAL FRAC NEC
.M625	Path.fracture - hand	M844	PATHOLOGICAL FRAC NEC
.M626	Path.fracture - pelvis/thigh	M844	PATHOLOGICAL FRAC NEC
.M627	Path.fracture - lower leg	M844	PATHOLOGICAL FRAC NEC
.M628	Path.fracture - ankle/foot	M844	PATHOLOGICAL FRAC NEC
.M62Z	Path.fracture - NOS	M844	PATHOLOGICAL FRAC NEC
N3310	Pathological # - thoracic vert	M844	PATHOLOGICAL FRAC NEC
N3311	Pathological # - lumbar vert.	M844	PATHOLOGICAL FRAC NEC
N3317	Fract of bone in neoplast dis	M844	PATHOLOGICAL FRAC NEC
N331C	Pathological # cervical vert	M844	PATHOLOGICAL FRAC NEC
N331y	Pathological fracture OS	M844	PATHOLOGICAL FRAC NEC
N331z	Pathological fracture NOS	M844	PATHOLOGICAL FRAC NEC

**Table 5. ICD-10 to READ Code Translation**

NyuCE	[X]#bone/neoplastic disease CE	M844	PATHOLOGICAL FRAC NEC
N339.	Residual foreign body in bone	M848	OTH DIS CONTINUITY BONE
NyuB5	[X]Oth diso/continuity of bone	M848	OTH DIS CONTINUITY BONE
N338z	Fracture malunion/nonunion NOS	M849	DIS CONTINUITY BONE UNSP
N3323	Monostotic fibrous dysplasia	M850	FIBR DYSPLAS(MONOSTOTIC)
N33zA	Skeletal fluorosis	M851	SKELETAL FLUOROSIS
N333.	Hyperostosis of skull	M852	HYPEROSTOSIS OF SKULL
N3330	Hyperostosis interna frontalis	M852	HYPEROSTOSIS OF SKULL
N3331	Leontiasis ossium	M852	HYPEROSTOSIS OF SKULL
N333z	Hyperostosis of skull NOS	M852	HYPEROSTOSIS OF SKULL
N335.	Osteitis condensans	M853	OSTEITIS CONDENSANS
N3350	Osteitis condensans ilii	M853	OSTEITIS CONDENSANS
.N335	Osteitis condensans	M853	OSTEITIS CONDENSANS
N3321	Solitary bone cyst	M854	SOLITARY BONE CYST
N3322	Aneurysmal bone cyst	M855	ANEURYSMAL BONE CYST
.M63.	Cyst of bone	M856	OTHER CYST OF BONE
N332.	Cyst of bone	M856	OTHER CYST OF BONE
N3320	Bone cyst (localised),unspecif	M856	OTHER CYST OF BONE
N332z	Cyst of bone NOS	M856	OTHER CYST OF BONE
NyuB6	[X]Other cyst of bone	M856	OTHER CYST OF BONE
.N332	Cyst of bone	M856	OTHER CYST OF BONE
N3324	Fibrous cortical defect	M858	O/SPEC DIS BNE DSTY/STRC
NyuB7	[X]O spc diso/bne dnsity+struc	M858	O/SPEC DIS BNE DSTY/STRC
NyuBB	[X]Erosion of bone	M858	O/SPEC DIS BNE DSTY/STRC
NyuBC	[X]Osteopenia	M858	O/SPEC DIS BNE DSTY/STRC
.585P	QUS heel - result osteopenic	M859	DIS BNE DSTY/STRC UNSP
.58EN	Lumbar DXA result osteopenic	M859	DIS BNE DSTY/STRC UNSP
.58EH	Hip DXA scan result osteopenic	M859	DIS BNE DSTY/STRC UNSP
.58EB	Heel DXA result osteopenic	M859	DIS BNE DSTY/STRC UNSP
58000	Forearm DXA result osteopenic	M859	DIS BNE DSTY/STRC UNSP
NyuB.	[X]Disorders/bone dens+structur	M859	DIS BNE DSTY/STRC UNSP

**Table 5. ICD-10 to READ Code Translation**

NyuBA	[X]Disord bone dens/struc,unsp	M859	DIS BNE DSTY/STRC UNSP
.58EW	Femor nec DEXA scan osteopenic	M859	DIS BNE DSTY/STRC UNSP